pharmaphorum| News & views on pharma and biotech’s evolving future

Digital

What US healthcare companies and medical researchers need to...

How Italy’s pioneering AI Law and the EU AI Act impacts US healthcare companies and medical researchers operating in Italy.

News

Lilly unveils employer scheme for weight-loss drug Zepbound

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

R&D

The GLP-1 Reckoning

News

PepGen slumps as FDA places hold on lead drug

Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.

News

Can GLP-1 drugs help tackle addiction?

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

Featured Content

Digital

What US healthcare companies and medical researchers need to...

How Italy’s pioneering AI Law and the EU AI Act impacts US healthcare companies and medical researchers operating in Italy.

R&D

The GLP-1 Reckoning

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

R&D

pharmaphorum podcast Episode 248, Andrew McKinnon, Medable

AI in clinical development & ‘white space’, with Andrew McKi...

Andrew McKinnon, senior vice president and executive general manager at Medable, discussesleveraging AI to transform & accelerate clinical development

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

Digital

Sponsored

Expert Directed Applied Intelligence: Redefining AI in Life ...

In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.

Newsletters and Deep Dive
digital magazine

Latest News

News

Lilly unveils employer scheme for weight-loss drug Zepbound

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

News

PepGen slumps as FDA places hold on lead drug

Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.

News

Can GLP-1 drugs help tackle addiction?

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

News

Hansa closes on FDA verdict for transplant drug imlifidase

The FDA has started reviewing Hansa's imlifidase for highly sensitised adults needing a kidney transplant, but not in the requested rapid timeframe.

Views & Analysis

Digital

What US healthcare companies and medical researchers need to...

How Italy’s pioneering AI Law and the EU AI Act impacts US healthcare companies and medical researchers operating in Italy.

Market Access

JPM 2026: What it revealed about biotech’s new reality

JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.

Sales & Marketing

Pharma’s search loophole is a preview of what comes next

PPC ads often contain so little text that they avoid direct claims. Many consist only of a brand name, a link, and limited copy.

Digital

Sponsored

Legacy data into living scientific memory

The pharmaceutical industry is racing to turn its data into scientific intelligence with AI. Now it’s possible to connect your data and tool ecosystem

Deep Dive

R&D

The GLP-1 Reckoning

R&D

GLP-1s: Five years that changed metabolic medicine

R&D

Redesigning obesity trials for a chronic disease era

R&D

The trust gap: GLP-1s and the new information economy of obe...

White Papers & Webinar

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Digital

Sponsored

Expert Directed Applied Intelligence: Redefining AI in Life ...

In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.

Sales & Marketing

Lumanity white paper - person at top of mountain range

Sponsored

The strategic imperative of Integrated Evidence Generation P...

Integrated Evidence Generation Planning (IEGP) is recognised as a strategic necessity for biopharmaceutical organisations.

Digital

White paper from Veeva on Clinical Data Industry Research

Sponsored

Data managers and CRAs warn of rising data quality risks due...

A new industry report uncovers the scope of a long-ignored problem in clinical trial operations.

Podcasts & Video

R&D

AI in clinical development & ‘white space’, with Andrew McKi...

Andrew McKinnon, senior vice president and executive general manager at Medable, discussesleveraging AI to transform & accelerate clinical development

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Market Access